TARDBP encodes TDP-43 (TAR DNA-binding protein of 43 kDa), a DNA/RNA-binding protein that is a major pathological hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Abnormal aggregation of TDP-43 in cytoplasmic inclusions is a defining feature of approximately 95% of ALS cases and 50% of FTD cases. [@chenplotkin2023]
TDP-43 is a ubiquitously expressed nuclear protein with essential functions in RNA processing. The protein localizes predominantly to the nucleus in healthy cells but redistributes to the cytoplasm in disease states, forming characteristic inclusions that define a new class of proteinopathies. This pathology is found not only in ALS and FTD but also in many other neurodegenerative diseases, making TDP-43 a central player in neurodegeneration research. [@neumann2006] [@arai2006]
| TDP-43 (TARDBP) |
|---|
| Gene | [TARDBP](/genes/tardbp) |
| UniProt ID | [Q13148](https://www.uniprot.org/uniprot/Q13148) |
| PDB ID | 2N4P, 5W5N, 6N3B |
| Protein Length | 414 amino acids |
| Molecular Weight | ~43 kDa |
| Subcellular Localization | Nucleus (healthy), Cytoplasm (disease) |
| Expression | Ubiquitous; high in brain and spinal cord |
¶ Molecular Biology and Structure
TDP-43 is a 414-amino acid protein with multiple functional domains:
N-Terminal Domain (1-76 aa):
- Contains the nuclear localization signal (NLS)
- Required for nuclear import
- Mediates protein-protein interactions
- Enables DNA binding
RNA Recognition Motif (RRM) Domain (106-262 aa):
- Highly conserved RNA-binding domain
- Recognizes (UG)n repeat sequences in RNA
- Binds both DNA and RNA with similar affinity
- Essential for most TDP-43 functions
- Contains two RNP motifs (RNP1 and RNP2)
Glycine-Rich Domain (274-414 aa):
- C-terminal region with low complexity
- Prone to aggregation
- Contains most disease-causing mutations (>50 known)
- Mediates interactions with other RNA-binding proteins
- Critical for protein solubility
Key Structural Features:
- The RRM domain has a classic β-α-β-fold RNA-binding motif
- The C-terminal domain is intrinsically disordered
- Post-translational modifications (phosphorylation, ubiquitination) affect function
- Forms multimers through C-terminal interactions
[@buratti2024]
In the normal state, TDP-43 participates in numerous RNA processing functions:
1. Alternative Splicing:
- Regulates inclusion/exclusion of exons
- Influences splice site selection
- Important for neuronal-specific splicing patterns
- Targets include CFTR, tau, and neuronal transcripts
2. mRNA Stability:
- Binds to 3' UTR regions
- Affects mRNA decay rates
- Regulates transcript stability
- Involved in RNA quality control
3. RNA Transport:
- Participates in mRNA trafficking to synapses
- Localizes to dendritic compartments
- Supports activity-dependent translation
- Important for synaptic plasticity
4. Transcription Regulation:
- Can act as transcriptional co-activator/repressor
- Modulates gene expression
- Interacts with transcriptional machinery
5. miRNA Processing:
- Associates with Drosha complex
- Affects miRNA biogenesis
- Links to post-transcriptional regulation
6. Stress Response:
- Transiently localizes to stress granules under cellular stress
- Helps regulate stress-response mRNAs
- Part of the cellular stress response machinery
[@lagier2009] [@da cruz2012]
ALS is a progressive neurodegenerative disease affecting upper and lower motor neurons. TDP-43 pathology is present in ~95% of ALS cases, making it the most common protein aggregate in this disease.
Pathology:
- TDP-43 is the major constituent of cytoplasmic inclusions in motor neurons
- Loss of nuclear TDP-43 and cytoplasmic accumulation is characteristic
- Inclusions are ubiquitin-positive but tau-negative
- Pathological phosphorylation at serine 409/410
- Fragmentation of full-length TDP-43 into ~25-35 kDa fragments
Genetics:
- Over 50 mutations in TARDBP cause familial and sporadic ALS
- Mutations primarily in the C-terminal glycine-rich domain
- Account for ~5% of familial ALS cases
- Provide direct evidence that TDP-43 dysfunction causes disease
- Include missense (e.g., A315T, G348C, Q331K) and truncation mutations
Pathogenic Mechanisms:
The precise mechanisms by which TDP-43 mutations cause disease remain under investigation:
- Loss of nuclear function: Mutations may impair RNA processing, leading to altered splicing and expression of essential neuronal genes
- Gain of toxic cytoplasmic function: Cytoplasmic aggregates may sequester essential proteins and RNAs
- Stress granule dysregulation: Aberrant stress granule dynamics contribute to pathology
- Mitochondrial dysfunction: TDP-43 affects mitochondrial gene expression
- Excitotoxicity: Altered glutamate transporter expression may contribute
[@rutherford2008] [@kabashi2010] [@sreedharan2011] [@gao2018]
FTD is a spectrum of neurodegenerative disorders characterized by progressive behavioral and language deficits. TDP-43 pathology is found in approximately 50% of FTD cases.
Pathology:
- TDP-43 inclusions in neurons and glia of frontal and temporal cortices
- Characteristic "type B" FTLD-TDP pathology
- Neuronal loss and gliosis in affected regions
- Subtypes based on distribution and pattern of inclusions
Spectrum Disease:
- ALS-FTD overlap syndrome with TDP-43 pathology
- Many patients show features of both conditions
- Shared genetic and pathological mechanisms
- Common in cases with C9orf72 expansions
Clinical Presentations:
- Behavioral variant FTD (bvFTD)
- Primary progressive aphasia (PPA)
- Semantic variant PPA
- Progressive nonfluent aphasia
[@neumann2022] [@li2018]
TDP-43 pathology is commonly observed in Alzheimer's disease:
Prevalence:
- TDP-43 pathology observed in ~30-50% of AD cases
- Often in limbic regions (hippocampus, amygdala)
- More common with increasing AD severity
- Often accompanies amyloid and tau pathology
Clinical Impact:
- May contribute to cognitive decline beyond AD pathology
- Associated with more rapid progression
- Often in limbic regions
- Can be a primary or secondary pathology
Relationship to AD:
- Specific TDP-43 strains may differ from ALS/FTD
- May interact with tau pathology
- Role in disease progression actively studied
[@manchester2017]
TDP-43 pathology is increasingly recognized in other conditions:
Parkinson's Disease:
- TDP-43 inclusions in some cases
- Often in older patients
- May contribute to disease progression
- Can be primary or secondary
Dementia with Lewy Bodies (DLB):
- TDP-43 pathology in ~15-20% of cases
- Often coexists with Lewy bodies
- May affect clinical phenotype
Huntington's Disease:
- TDP-43 co-pathology in some patients
- May affect disease expression
- Interaction with mutant huntingtin
Other Conditions:
- Chronic traumatic encephalopathy
- Some epilepsy cases
- Inclusion body myositis
[@johansson2019]
The fundamental question in TDP-43 proteinopathy is whether disease results from loss of nuclear function, gain of toxic cytoplasmic function, or both.
Loss of Nuclear Function Evidence:
- Reduced nuclear TDP-43 in patient tissue
- Mutations impair RNA binding
- Altered splicing of target transcripts
- Nuclear clearance mechanisms may contribute
Cytoplasmic Gain of Function Evidence:
- Cytoplasmic inclusions are pathological hallmark
- Overexpression of wild-type TDP-43 causes toxicity
- Cytoplasmic TDP-43 disrupts mitochondrial function
- Sequestration of essential RNAs in aggregates
The current consensus suggests both mechanisms contribute to disease, and therapeutic approaches may need to address both.
[@woerner2016] [@barmada2010]
TDP-43 aggregation is central to disease pathogenesis:
Aggregation Process:
- C-terminal domain drives aggregation
- Low complexity region enables liquid-liquid phase separation
- Pathological phosphorylation at S409/410 promotes aggregation
- Truncation fragments seed aggregation
- Prion-like spread between cells
Cell-to-Cell Transmission:
- TDP-43 aggregates can transfer between cells
- May propagate pathology in a prion-like manner
- Observed in cell culture and animal models
- Could explain spread along neural networks
Oligomer Formation:
- Soluble oligomers may be toxic species
- Multiple oligomeric species identified
- Different from mature inclusions
- Therapeutic target
[@nonaka2016] [@budini2012]
¶ Stress Granules and TDP-43
Stress granules are cytoplasmic RNA-protein aggregates that form during cellular stress. TDP-43 transiently localizes to stress granules, and this process is dysregulated in disease.
Normal Stress Granule Function:
- Form under stress to protect mRNAs
- Contain translationally stalled mRNPs
- Disassemble when stress resolves
Dysregulation in Disease:
- TDP-43 forms persistent stress granule-like inclusions
- Mutations alter stress granule dynamics
- Stress granules may seed pathological aggregates
- Chronic stress may drive pathology
Therapeutic Implications:
- Modulating stress granule dynamics may help
- Preventing TDP-43 recruitment to stress granules
[@pollock2014]
ASOs targeting TARDBP mRNA represent the most advanced therapeutic approach:
Mechanism:
- ASOs bind to TARDBP mRNA
- RNase H-mediated degradation reduces TDP-43 protein
- Can be delivered to CNS via intrathecal injection
- Reduce pathological TDP-43
Clinical Status:
- Multiple ASO programs in clinical trials
- Early-phase trials in ALS patients
- Some success in reducing CSF TDP-43
- Challenges: delivery, timing, patient selection
Approaches:
- Gene knockdown ASOs
- Allele-selective ASOs for specific mutations
- Combination approaches
[@bhardwaj2022] [@petrov2017]
Small molecules targeting TDP-43 aggregation are under development:
Target Areas:
- Prevent aggregation of TDP-43
- Promote clearance of aggregates
- Modulate post-translational modifications
Challenges:
- Target engagement in CNS
- Compound properties for brain penetration
- Disease stage for intervention
Current Candidates:
- Aggregation inhibitors in screening
- Compounds targeting phosphorylation
- Molecules promoting autophagy
Viral vector delivery of corrected TARDBP or modulators:
Approaches:
- AAV-delivered shRNA/siRNA for knockdown
- Gene delivery of wild-type TDP-43
- CRISPR-based approaches
- RNA-binding protein modulators
Challenges:
- Delivery to appropriate CNS regions
- Achieving sufficient knock-down
- Avoiding off-target effects
- Safety considerations
[@hazz2020]
¶ Symptomatic and Disease-Modifying Approaches
Symptomatic:
- Standard ALS/FTD management
- Riluzole, edaravone in ALS
- Supportive care
- Symptom-targeted therapies
Disease-Modifying:
- Modulating TDP-43 pathology
- Targeting upstream mechanisms
- Combination approaches
| Partner |
Interaction Type |
Function |
| FUS |
RNA-binding proteins |
ALS/FTD overlap |
| TIA1 |
Stress granule component |
Stress granule dynamics |
| hnRNPs |
RNA processing |
Splicing regulation |
| Stathmin |
Microtubule regulation |
Transport |
| p53 |
Transcription |
Apoptosis regulation |
| Mitochondrial proteins |
Function |
Energy metabolism |
| Ubiquitin |
Modification |
Degradation |
- Structural biology: Atomic resolution of TDP-43 aggregates
- Strains: Different TDP-43 strains in different diseases
- Biomarkers: CSF and imaging biomarkers
- iPSC models: Patient-derived neurons
- Gene therapy: Viral delivery systems
- TDP-43 levels in CSF
- PET ligands for TDP-43 aggregates
- Genetic testing for mutations
- Fluid biomarkers for disease progression
- TARDBP transgenic mice: Overexpress wild-type or mutant TDP-43
- Knockin models: Express human mutations in endogenous gene
- Conditional models: Inducible expression systems
- Optic nerve models: Visual system studies
- Motor neuron degeneration
- Behavioral deficits
- Gliosis
- Protein aggregation
- Shorter lifespan
[@fratta2021]
- Buratti E et al., TDP-43 functions in RNA metabolism and disease, Nat Rev Neurosci (2024)
- Chen-Plotkin AS et al., TDP-43 in neurodegeneration: from mechanisms to therapy, Nat Rev Neurol (2023)
- Neumann M et al., TDP-43 pathology in ALS/FTD: new insights, Acta Neuropathol (2022)
- Neumann M et al., Ubiquitinated TDP-43 in frontotemporal lobar degeneration and ALS, Science (2006)
- Arai T et al., TDP-43 is a component of ubiquitin-positive tau-negative inclusions, Biochem Biophys Res Commun (2006)
- Lagier-Tourenne C et al., Rethinking ALS, FTD, and TDP-43: a molecular perspective, Trends Neurosci (2009)
- Da Cruz S et al., TDP-43 and FUS: a nuclear affair, Trends Neurosci (2012)
- Rutherford NJ et al., TARDBP mutations in sporadic and familial ALS, Proc Natl Acad Sci USA (2008)
- Kabashi E et al., TARDBP mutations in French Canadian familial ALS, Nat Genet (2010)
- Sreedharan J et al., TDP-43 mutations in familial and sporadic ALS, Science (2011)
- Gao J et al., ALS mutations in TDP-43 and its nuclear function, Nat Rev Neurol (2018)
- Woerner A et al., Cytoplasmic TDP-43 induces neuronal death through p53/Siah1 pathway, Cell (2016)
- Barmada SJ et al., Cytoplasmic TDP-43 induces neuronal degeneration, J Neurosci (2010)
- Nonaka T et al., Prion-like propagation of TDP-43 aggregates in ALS, Acta Neuropathol (2016)
- Budini M et al., TDP-43 aggregation in neurodegeneration, Nat Rev Neurol (2012)
- Pollock JA et al., Stress granule formation and TDP-43 pathology, J Cell Sci (2014)
- McAlary L et al., TDP-43 oligomerization and aggregation in ALS, Neurobiol Dis (2015)
- Li Q et al., TDP-43 cleavage and aggregation in FTD spectrum, Acta Neuropathol (2018)
- Manchester LC et al., TDP-43 in Alzheimer's disease co-pathology, Neurobiol Aging (2017)
- Johansson I et al., TDP-43 in Parkinson's disease and dementia with Lewy bodies, Brain (2019)
- Tam OH et al., Postmortem cortex samples show TDP-43 pathology in ALS/FTD, Nat Neurosci (2019)
- Fratta P et al., TDP-43 animal models of ALS/FTD, Nat Rev Neurol (2021)
- Bhardwaj G et al., Antisense oligonucleotide therapy for TDP-43 proteinopathies, Nat Rev Drug Discov (2022)
- Petrov D et al., TDP-43-based therapeutics for ALS/FTD, Mol Ther (2017)
- Hazzi E et al., Gene therapy approaches for TDP-43 proteinopathy, Gene Ther (2020)